

## Terms and Conditions (Version 2)

### Warwick-Wellcome Trust Translational Partnership

All award holders must:

- Follow the Wellcome standard Grant Conditions that apply to this award ([www.wellcome.ac.uk/funding/managing-grant/grant-conditions](http://www.wellcome.ac.uk/funding/managing-grant/grant-conditions)). Award holders must follow Wellcome funding policies ([www.wellcome.ac.uk/funding/managing-grant/policy-and-position-statements](http://www.wellcome.ac.uk/funding/managing-grant/policy-and-position-statements))
- The funding may be used to support directly incurred costs (e.g. staff, consumables, travel & subsistence, other project costs) at 100% FEC. Indirect, estate costs and other directly allocated costs are not eligible. The funding must be used to carry out the project as detailed in the application. Wellcome should only be charged in arrears for actual expenditure incurred.
- Funds must be spent in accordance with the University of Warwick's established procurement policies. Control of expenditure awarded on the grant is governed by the normal standards and procedures at Warwick and will be covered by any formal audit arrangements that exist at Warwick.
- The principles of good research practice are followed, including clinical governance, data sharing and preservation in line with Wellcome Grant Conditions and the Policies and Positions;
- Where Wellcome-funded Intellectual Property arises from your award, you must obtain Wellcome prior written consent (not to be unreasonably withheld in circumstances where it is an appropriate means of achieving charitable public benefit) before you make any commercial use of, or grant to any third party any exploitation rights over, the Wellcome-funded Intellectual Property. As a condition of granting consent, Warwick will require you to accept Wellcome's standard revenue- and equity-sharing agreement as set out in the Grant Conditions. Please liaise with R&IS and Warwick Ventures.
- On accepting the award, the grant holder is agreeing to both the Wellcome Bullying and Harassment Policy and the University of Warwick being able to supply the information required to comply with these terms. The full policy can be found at: <https://wellcome.ac.uk/funding/guidance/bullying-and-harassment-policy>. Further details are listed below.
- Any outcomes of the award that are suitable for publication must be published in accordance with the publication provisions in the Wellcome Grant Conditions and Policies and Provisions which include Wellcome's Open Access policy.
- Consult Wellcome's Media Office before the release of any announcements, press statement or other media presentation concerning the award.
- Individuals and Departments can demonstrate that they cannot support the project or activity from existing individual or departmental discretionary funds.
- Funds must be spent according to an agreed profile, failure to spend will result in a claw-back event. Requests to reallocate funds and/or to alter the spending profile must be made to [Wellcome-Translation@warwick.ac.uk](mailto:Wellcome-Translation@warwick.ac.uk).
- Any over-spends become the responsibility of the host Department or Departments.
- Funds must be spent by 30 November 2022. No extensions are possible.
- There are no significant additional space implications that cannot be accommodated within the Warwick Department(s) and external organisation(s) involved.
- Appropriate ethical approval must be sought and granted where necessary before the start of the project.

- The appropriate contractual arrangements between Warwick and Industrial partner(s) will be put in place as required where applicable. The Industrial partner(s) will need to accept the Wellcome Grant Conditions, in particular in regards to Intellectual Property and revenue-sharing.
- Award holders are required to actively participate in activities related to the Warwick-Wellcome Translational Partnership, such as symposia and dissemination events, and to support the University in achieving the key deliverables as listed below.
- Interim, Annual and Final reports must be provided via email to [Wellcome-Translation@warwick.ac.uk](mailto:Wellcome-Translation@warwick.ac.uk) by the deadlines indicated (a template will be provided).

### **Further details to the Wellcome Bullying and Harassment Policy**

On accepting the Wellcome award, the grant holder is agreeing to both the Wellcome Bullying and Harassment Policy and the University of Warwick being able to supply the information required to comply with these terms. The policy requires that when an investigation into an allegation has been opened by the University that Wellcome's Director of Grants must be informed of this, which should include a brief factual statement about the nature of the allegation.

The Wellcome reserve the right to ask for the name of the employee whose conduct is being investigated, where they consider that they have a legitimate interest in doing so. This applies to any university employee who is associated with: a grant application (either as a lead applicant, sponsor or supervisor); a Wellcome grant and a Wellcome advisory committee.

Once the investigation has completed and any final appeal has been heard, the university is required to confirm to Wellcome: if the allegation was upheld; the findings of the investigation and if any are sanctions being imposed.

Wellcome reserve the right to request a copy of the investigation report, where they consider they have a legitimate interest in doing so.

### **Key Deliverables**

The Warwick-Wellcome Translational Partnership will focus on investing in fellowships and projects aimed at exploiting emerging impact in the science of early life, tissue models of human disease and disease control and prevention. The Warwick-Wellcome Translational Partnership will provide supporting expertise in impact delivery and will strengthen links to partner institutions in industry and the local hospital network.

Specifically, the Warwick-Wellcome Translational Partnership has the following projects outputs for 2020-22:

- 1) Increase in number of MRC/UKRI/CRUK/Wellcome translational/Innovation research funding applications.
- 2) Establishment of new clinician-driven translational research projects (UHCW-UoW interface).
- 3) Increase in number of invention disclosures.
- 4) Translational fellows winning follow-on fellowships, joining industry or driving spin-outs.
- 5) New industry engagement through reverse fellowships, research partnerships and investment.
- 6) Facilitation of new translational research through the Interdisciplinary Biomedical Research Building (IBRB).
- 7) Emergence of translational projects from Wellcome-funded research base.
- 8) Percentage Wellcome-funded researchers engaged in translation.
- 9) Number of Researchers who have actively engaged with the TPA.
- 10) The number/range of external advisors engaged to support translational projects.
- 11) Website traffic and qualitative feedback on tools or events run as part of Partnership.